Redeye initiates coverage of ExpreS2ion Biotech, a clinical-stage Scandinavian biotech company developing differentiated immunotherapies based on its phase III–validated ExpreS2 protein expression platform. Supported by compelling preclinical data and early clinical progress, its lead asset ES2B-C001 is targeting the multibillion-dollar HER2-expressing cancer market. We see meaningful long-term upside as the company advances a novel, multi-targeting cancer vaccine with blockbuster potential.
LÄS MER
